Cargando…

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel

Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a ke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerding, Heinrich, Monés, Jordi, Tadayoni, Ramin, Boscia, Francesco, Pearce, Ian, Priglinger, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/ https://www.ncbi.nlm.nih.gov/pubmed/25075121 http://dx.doi.org/10.1136/bjophthalmol-2014-305041

Ejemplares similares

Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
por: Lotery, Andrew, et al.
Publicado: (2021)

Disease-modifying effects of ranibizumab for central retinal vein occlusion
por: Huang, Jason M., et al.
Publicado: (2021)

Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study
por: Pearce, Ian, et al.
Publicado: (2020)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
por: Dogan, Emine, et al.
Publicado: (2018)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018)

Branch Retinal Vein Occlusion followed by Central Retinal Vein Occlusion
por: Moradian, Siamak, et al.
Publicado: (2009)

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
por: Callizo, Josep, et al.
Publicado: (2019)

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022)

Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy
por: McAllister, Ian L, et al.
Publicado: (2021)

Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
por: Aissopou, Evaggelia, et al.
Publicado: (2023)

Relationship between metamorphopsia and inner retinal microstructure following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Sugiura, Yoshimi, et al.
Publicado: (2021)

Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
por: Yasuda, Kanako, et al.
Publicado: (2023)

Pachychoroid disease and its association with retinal vein occlusion: a case–control study
por: Keidel, Leonie F., et al.
Publicado: (2021)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer, Michael A, et al.
Publicado: (2013)

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
por: Lotery, A J, et al.
Publicado: (2015)

Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2016)

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017)

Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Oshiro, Ayano, et al.
Publicado: (2021)

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
por: Ni, Weiyi, et al.
Publicado: (2021)

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022)

Combined Branch Retinal Artery and Central Retinal Vein Occlusion: A Systematic Review
por: Pinna, Antonio, et al.
Publicado: (2023)

Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report
por: Monés, Jordi, et al.
Publicado: (2013)

Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020)

Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
por: Menke, Marcel N., et al.
Publicado: (2016)

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure
por: Liu, Haiyang, et al.
Publicado: (2018)

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
por: Lloyd Clark, W., et al.
Publicado: (2019)

Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study
por: Kishishita, Shuta, et al.
Publicado: (2022)

Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion
por: Ozcift, Seda Gurakar, et al.
Publicado: (2023)

Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report
por: Muramatsu, Daisuke, et al.
Publicado: (2015)

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
por: Unsal, Erkan, et al.
Publicado: (2015)

Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
por: Brogan, Kerr, et al.
Publicado: (2018)

Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser
por: Wang, Dingding, et al.
Publicado: (2019)

Potential roles of MNREAD acuity charts and contrast/glare sensitivity in Ranibizumab treatment of branch retinal vein occlusion
por: Tanabe, Hirotaka, et al.
Publicado: (2020)

Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion
por: Dikel, Nevin Hande, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l54ihu5tnbfdrekat1vancs9bd